BioWorld

Oct. 4, 2006

Biogen Gains Rights To UCB's CDP323 In $200M Partnership

Adding a fifth product to its portfolio of approved and investigational multiple sclerosis therapies, Biogen Idec Inc. agreed to collaborate on CDP323, an oral alpha-4 integrin inhibitor discovered by UCB. (BioWorld Today) Read More

MacroGenics Gets $63M From Government, Mostly For WNV

In Pandemic Flu, Strong Immune Response May Be Good, Or Not

Xanthus In-Licenses U.S. Rights To Oral Fludarabine

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...